Atomoxetina: luces y sombras

Atomoxetine is a noradrenaline reuptake inhibitor that is being studied for use in the treatment of attention-deficit/hyperactivity disorder (ADHD) in Spain. To date, a variety of open-label, randomized, double-blind, placebo-controlled trials in children, adolescents and adults have been published. We present the pharmacological properties and indications of atomoxetine and discuss published evidence on its efficacy in ADHD and comorbid disorders. The adverse effects profile and safety concerns of this drug are critically reviewed.